NCT06031636View on ClinicalTrials.gov

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

RecruitingOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Malignant Pleural Mesothelioma, Advanced
Interventions
DRUG

Oncolytic Adenovirus H101

The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles

DRUG

Programmed death receptor-1 inhibitor

The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical Unversity Second Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Second Hospital

OTHER